Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis: Implications for cellular surrogate marker analysis of antiangiogenesis

Cancer Cell

Volumn 7, Issue 1, 2005, Pages 101-111

  Shaked, Yuval ^a   Bertolini, Francesco ^b   Man, Shan ^a   Rogers, Michael S ^c   Cervi, Dave ^a,d   Foutz, Thomas ^b   Rawn, Kimberley ^a   Voskas, Daniel ^a,d   Dumont, Daniel J ^a,d   Ben David, Yaacov ^a,d   Lawler, Jack ^e   Henkin, Jack ^f   Huber, Jim ^g   Hicklin, Daniel J ^g   D'Amato, Robert J ^c   Kerbel, Robert S ^a,d  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^c BOSTON CHILDREN S HOSPITAL   (United States)

^d UNIVERSITY OF TORONTO   (Canada)

^e HARVARD MEDICAL SCHOOL   (United States)

^f ABBOTT LABORATORIES   (United States)

^g ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOPOIETIN RECEPTOR; BASIC FIBROBLAST GROWTH FACTOR RECEPTOR; THROMBOSPONDIN 1; VASCULOTROPIN ANTIBODY; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; DOSE RESPONSE; FLOW CYTOMETRY; GENETIC VARIABILITY; INBRED STRAIN; INDUCED MUTATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPECIES COMPARISON; VALIDATION PROCESS;

ANIMALIA;

EID: 19944432454     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccr.2004.11.023     Document Type: Article

References (49)

1. Asahara T., Murohara T., Sullivan A., Silver M., van der Zee R., Li T., Witzenbichler B., Schatteman G., Isner J.M. Isolation of putative progenitor endothelial cells for angiogenesis. Science. 275:1997;964-967
2. Asahara T., Takahashi T., Masuda H., Kalka C., Chen D., Iwaguro H., Inai Y., Silver M., Isner J.M. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J. 18:1999;3964-3972
3. Bertolini F., Mingrone W., Alietti A., Ferrucci P.F., Cocorocchio E., Peccatori F., Cineri S., Mancuso P., Corsini C., Burlini A., et al. Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers. Ann. Oncol. 12:2001;987-990
4. Bertolini F., Paul S., Mancuso P., Monestiroli S., Gobbi A., Shaked Y., Kerbel R.S. Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res. 63:2003;4342-4346
5. Bocci G., Francia G., Man S., Lawler J., Kerbel R.S. Thrombospondin-1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. Proc. Natl. Acad. Sci. USA. 100:2003;12917-12922
6. Bocci G., Man S.M., Green S.K., Francia G., Ebos J.M.L., du Manoir J.M., Emmenegger U., Ma L., Thorpe P., Davidoff A.M., et al. Increased plasma VEGF as a surrogate marker for optimal therapeutic dosing of VEGFR-2 monoclonal antibodies. Cancer Res. 64:2004;6616-6625
7. Bouck N., Stellmach V., Hsu S.C. How tumors become angiogenic. Adv. Cancer Res. 69:1996;135-174
8. Capillo M., Mancuso P., Gobbi A., Monestiroli S., Pruneri G., Dell'Agnola C., Martinelli G., Shultz L., Bertolini F. Continuous infusion of endostatin inhibits differentiation, mobilization, and clonogenic potential of endothelial cell progenitors. Clin. Cancer Res. 9:2003;377-382
9. Cristofanilli M., Charnsangavej C., Hortobagyi G.N. Angiogenesis modulation in cancer research. novel clinical approaches Nat. Rev. Drug Discov. 1:2002;415-426
10. Crosby J.R., Kaminski W.E., Schatteman G., Martin P.J., Raines E.W., Seifert R.A., Bowen-Pope D.F. Endothelial cells of hematopoietic origin make a significant contribution to adult blood vessel formation. Circ. Res. 87:2000;728-730
11. Garcia-Barros M., Paris F., Cordon-Cardo C., Lyden D., Rafii S., Haimovitz-Friedman A., Fuks Z., Kolesnick R. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science. 300:2003;1155-1159
12. Gothert J.R., Gustin S.E., Van Eekelen A.M., Schmidt U., Hall M.A., Jane S.M., Green A.R., Gottgens B., Izon D.J., Begley C.G. Genetically tagging endothelial cells in vivo. bone marrow-derived cells do not contribute to tumor endothelium Blood. 104:2004;1769-1777
13. Hanahan D., Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 86:1996;353-364
14. Heil M., Ziegelhoeffer T., Mees B., Schaper W. A different outlook on the role of bone marrow stem cells in vascular growth. bone marrow delivers software not hardware Circ. Res. 94:2004;573-574
15. Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth H., Helm W., Berlin J., Baron A., Griffing S., Holmgren E., et al. Addition of bevacizumab (rhuMab VEGF) to bolus IFL in the first line treatment of patients with metastatic colorectal cancer. results of a randomized phase III trial N. Engl. J. Med. 350:2004;2335-2342
16. Jain R.K., Duda D.G. Role of bone marrow-derived cells in tumor angiogenesis and treatment. Cancer Cell. 3:2003;515-516
17. Kenyon B.M., Voest E.E., Chen C.C., Flynn E., Folkman J., D'Amato R.J. A model of angiogenesis in the mouse cornea. Invest. Ophthalmol. Vis. Sci. 37:1996;1625-1632
18. Kerbel R.S., Kamen B.A. Antiangiogenic basis of low-dose metronomic chemotherapy. Nat. Rev. Cancer. 4:2004;423-436
19. Klement G., Baruchel S., Rak J., Man S., Clark K., Hicklin D., Bohlen P., Kerbel R.S. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J. Clin. Invest. 105:2000;R15-R24
20. Lawler J., Sunday M., Thibert V., Duquette M., George E.L., Rayburn H., Hynes R.O. Thrombospondin-1 is required for normal murine pulmonary homeostasis and its absence causes pneumonia. J. Clin. Invest. 101:1998;982-992
21. Li H., Gerald W.L., Benezra R. Utilization of bone marrow-derived endothelial cell precursors in spontaneous prostate tumors varies with tumor grade. Cancer Res. 64:2004;6137-6143
22. Lyden D., Hattori K., Dias S., Costa C., Blaikie P., Butros L., Chadburn A., Heissig B., Marks W., Witte L., et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat. Med. 7:2001;1194-1201
23. Machein M.R., Renninger S., Lima-Hahn E., Plate K.H. Minor contribution of bone marrow-derived endothelial progenitors to the vascularization of murine gliomas. Brain Pathol. 13:2003;582-597
24. Maisonpierre P.C., Goldfarb M., Yancopoulos G.D., Gao G. Distinct rat genes with related profiles of expression define a TIE receptor tyrosine kinase family. Oncogene. 8:1993;1631-1637
25. McDonald D.M., Teicher B.A., Stetler-Stevenson W., Ng S.S., Figg W.D., Folkman J., Hanahan D., Auerbach R., O'Reilly M., Herbst R., et al. Report from the society for biological therapy and vascular biology faculty of the NCI workshop on angiogenesis monitoring. J. Immunother. 27:2004;161-175
26. Miquerol L., Langille B.L., Nagy A. Embryonic development is disrupted by modest increases in vascular endothelial growth factor gene expression. Development. 127:2000;3941-3946
27. Monestiroli S., Mancuso P., Burlini A., Pruneri G., Dell'Agnola C., Gobbi A., Martinelli G., Bertolini F. Kinetics and viability of circulating endothelial cells as surrogate angiogenesis marker in an animal model of human lymphoma. Cancer Res. 61:2001;4341-4344
28. Morgan B., Thomas A.L., Drevs J., Hennig J., Buchert M., Jivan A., Horsfield M.A., Mross K., Ball H.A., Lee L., et al. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases. results from two phase I studies J. Clin. Oncol. 21:2003;3955-3964
29. Park J.W., Kerbel R.S., Kelloff G.J., Barrett J.C., Chabner B.A., Parkinson D.R., Peck J., Ruddon R.W., Sigman C.C., Slamon D.J. Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development. Clin. Cancer Res. 10:2004;3885-3896
30. Parulekar W.R., Eisenhauer E.A. Phase I trial design for solid tumor studies of targeted, non-cytotoxic agents. theory and practice J. Natl. Cancer Inst. 96:2004;990-997
31. Prewett M., Huber J., Li Y., Santiago A., O'Connor W., King K., Overholser J., Hooper A., Pytowski B., Witte L., et al. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res. 59:1999;5209-5218
32. Rabascio C., Muratori E., Mancuso P., Calleri A., Raia V., Foutz T., Cinieri S., Veronesi G., Pruneri G., Lampertico P., et al. Assessing tumor angiogenesis. increased circulating VE-cadherin RNA in patients with cancer indicates viability of circulating endothelial cells Cancer Res. 64:2004;4373-4377
33. Rafii S., Lyden D., Benezra R., Hattori K., Heissig B. Vascular and haematopoietic stem cells. novel targets for anti-angiogenesis therapy? Nat. Rev. Cancer. 2:2002;826-835
34. Rajantie, I., Ilmonen, M., Alminaite, A., Ozerdem, U., Alitalo, K., and Salven, P. (2004). Adult bone marrow-derived cells recruited during angiogenesis comprise precursors for periendothelial vascular mural cells. Blood 104, 2084-2086 Published online June 10, 2004. 10.1182/blood-2004-01-0336.
35. Rehman J., Li J., Orschell C.M., March K.L. Peripheral blood "endothelial progenitor cells" are derived from monocyte/macrophages and secrete angiogenic growth factors. Circulation. 107:2003;1164-1169
36. Reiher F.K., Volpert O.V., Jimenez B., Crawford S.E., Dinney C.P., Henkin J., Haviv F., Bouck N.P., Campbell S.C. Inhibition of tumor growth by systemic treatment with thrombospondin-1 peptide mimetics. Int. J. Cancer. 98:2002;682-689
37. Rohan R.M., Fernandez A., Udagawa T., Yuan J., D'Amato R.J. Genetic heterogeneity of angiogenesis in mice. FASEB J. 14:2000;871-876
38. Ruzinova M.B., Schoer R.A., Gerald W., Egan J.E., Pandolfi P.P., Rafii S., Manova K., Mittal V., Benezra R. Effect of angiogenesis inhibition by Id loss and the contribution of bone-marrow-derived endothelial cells in spontaneous murine tumors. Cancer Cell. 4:2003;277-289
39. Sarao R., Dumont D.J. Conditional transgene expression in endothelial cells. Transgenic Res. 7:1998;421-427
40. Sato T.N., Tozawa Y., Deutsch U., Wolburg-Buchholz K., Fujiwara Y., Gendron-Maguire M., Gridley T., Wolburg H., Risau W., Qin Y. Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature. 376:1995;70-74
41. Schuch G., Heymach J.V., Nomi M., Machluf M., Force J., Atala A., Eder J.P. Jr., Folkman J., Soker S. Endostatin inhibits the vascular endothelial growth factor-induced mobilization of endothelial progenitor cells. Cancer Res. 63:2003;8345-8350
42. Shaw J.P., Basch R., Shamamian P. Hematopoietic stem cells and endothelial cell precursors express Tie-2, CD31 and CD45. Blood Cells Mol. Dis. 32:2004;168-175
43. Shibuya T., Mak T.W. Isolation and induction of erythroleukemic cell lines with properties of erythroid progenitor burst-forming cell (BFU-E) and erythroid precursor cell (CFU-E). Proc. Natl. Acad. Sci. USA. 80:1983;3721-3725
44. Sikder H., Huso D.L., Zhang H., Wang B., Ryu B., Hwang S.T., Powell J.D., Alani R.M. Disruption of Id1 reveals major differences in angiogenesis between transplanted and autochthonous tumors. Cancer Cell. 4:2003;291-299
45. Stoll B.R., Migliorini C., Kadambi A., Munn L.L., Jain R.K. A mathematical model of the contribution of endothelial progenitor cells to angiogenesis in tumors. implications for anti-angiogenic therapy Blood. 102:2003;2555-2561
46. Viloria-Petit A.M., Miguerol L., Yu J.L., Gertenstein M., Sheehan C., May L., Henkin J., Lobe C., Nagy A., Kerbel R.S., Rak J. Contrasting effects of VEGF gene disruption in embryonic stem cell-derived versus oncogene-induced tumors. EMBO J. 22:2003;4091-4102
47. Voswinckel R., Ziegelhoeffer T., Heil M., Kostin S., Breier G., Mehling T., Haberberger R., Clauss M., Gaumann A., Schaper W., Seeger W. Circulating vascular progenitor cells do not contribute to compensatory lung growth. Circ. Res. 93:2003;372-379
48. Willett C.G., Boucher Y., di Tomaso E., Duda D.G., Munn L.L., Tong R.T., Chung D.C., Sahani D.V., Kalva S.P., Kozin S.V., et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat. Med. 10:2004;145-147
49. Ziegelhoeffer T., Fernandez B., Kostin S., Heil M., Voswinckel R., Helisch A., Schaper W. Bone marrow-derived cells do not incorporate into the adult growing vasculature. Circ. Res. 94:2004;230-238